Targets › TP53
22 programs from 20 companies in 36 trials: 17 Phase 1, 10 Phase 2, 8 Phase 3, 1 Phase 4; Oncology, Infectious disease; next expected readout Dec 2026.
Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence. Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. (UniProt, P04637)
Open in Phaseline: the race on TP53, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Precigen | Zopapogene imadenovec p53 gene therapy delivered via adenoviral vector | TP53 | Phase 4 | Recurrent Respiratory Papillomatosis | Dec 2027 |
| Shanghai Jiao Tong University School of Medicine | Fludarabine, Busulfan and Melphalan (Flu-Bu-Mel) Dual alkylating agents with purine nucleoside analog; busulfan and melphalan are DNA-alkyl | FLT3, TP53 | Phase 3 | Acute Myeloid Leukemia; Toxicities | Dec 2026 |
| Kartos Therapeutics | Navtemadlin (KRT-232) Tumour suppressor p53/oncoprotein Mdm2 inhibitor | TP53, MDM2 | Phase 3 | Myelofibrosis; Polycythemia Vera; Endometrial Cancer; Diffuse Large B Cell Lymphoma … | Dec 2026 |
| Sun Yat-sen University | TPF induction chemotherapy Combination chemotherapy: polymeric micellar paclitaxel (taxane microtubule inhibitor), ci | Tubulin, TP53 | Phase 3 | Nasopharyngeal Carcinoma | Dec 2026 |
| First Affiliated Hospital, Sun Yat-Sen University | Concurrent Chemotherapy (Cisplatin) Platinum-based alkylating agent | TP53 | Phase 3 | Locally Advanced Nasopharyngeal Carcinoma | Aug 2027 |
| First Affiliated Hospital, Sun Yat-Sen University | Induction Chemotherapy (TPF regimen) Docetaxel, cisplatin, and 5-fluorouracil combination | Tubulin, TP53, TYMS, RRM1 | Phase 3 | Locally Advanced Nasopharyngeal Carcinoma | Aug 2027 |
| OSE Immunotherapeutics | OSE2101 peptidic cancer vaccine with nine HLA-A2-restricted epitopes targeting tumor-associated an | TP53, ERBB2, CEA, MAGEA2, MAGEA3 | Phase 3 | Patients With Non-Small Cell Lung Cancer; Solid Advanced Tumor | Dec 2027 |
| Institute of Hematology & Blood Diseases Hospital, China | DVRd Daratumumab (CD38 monoclonal antibody), Velcade (proteasome inhibitor), and dexamethasone | PSMD1, TP53, MYC | Phase 2 | Multiple Myeloma | Dec 2026 |
| SynerGene Therapeutics | SGT-53 p53 gene therapy delivered by lipid nanoparticles | TP53 | Phase 2 | Metastatic Pancreatic Cancer | Dec 2026 |
| Centre Leon Berard | Siremadlin (HDM201) Tumour suppressor p53/oncoprotein Mdm2 inhibitor | TP53, MDM2 | Phase 2 | Malignant Solid Tumor; Advanced Soft-tissue Sarcoma | Feb 2027 |
| City of Hope Medical Center | Modified Vaccinia Virus Ankara Vaccine Expressing p53 p53 tumor antigen vaccine using modified vaccinia virus ankara | TP53 | Phase 2 | Recurrent Platinum-Resistant Fallopian Tube Carcinoma; Adult Solid Neoplasm | Apr 2027 |
| Fondazione Ricerca Traslazionale | Tedopi Cancer vaccine inducing cytotoxic T-lymphocytes against tumor-associated antigens (CEA, p5 | CEA, TP53, ERBB2, MAGE2, MAGE3 | Phase 2 | Metastatic Non Small Cell Lung Cancer | Sep 2027 |
| Sarcoma Oncology Research Center, LLC | Trabectedin Alkylating agent that binds to DNA and induces cell death | TP53 | Phase 2 | Sarcoma; Advanced Soft Tissue Sarcoma | Dec 2030 |
| Medical University of Vienna | Cisplatin DNA-damaging platinum agent; primary mechanism through DNA crosslinking and induction of a | TP53 | Phase 2 | Uterine Cervical Neoplasms | Apr 2031 |
| PMV Pharmaceuticals | rezatapopt p53 reactivator selective for TP53 Y220C mutation | TP53 | Phase 1 | Advanced Solid Tumor; TP53 Y220C Mutation; Myelodysplastic Syndrome | Dec 2026 |
| Chinese PLA General Hospital | TP53-EphA-2-CAR-DC TP53 mutant peptide-loaded, EphA2-targeting CAR dendritic cell vaccine | TP53, EPHA2 | Phase 1 | Solid Tumor, Adult | Dec 2026 |
| Jacobio Pharmaceuticals | JAB-30355 TP53 Y220C mutant-selective stabilizer | TP53 | Phase 1 | Solid Tumors | Jan 2027 |
| AeRang Kim | Alrizomadlin (APG-115) Tumour suppressor p53/oncoprotein Mdm2 inhibitor | TP53, MDM2 | Phase 1 | Malignant Peripheral Nerve Sheath Tumor (MPNST) | Oct 2027 |
| City of Hope Medical Center | Minnelide Triptolide analog; prodrug that releases triptolide via phosphatase activation; inhibits R | TP53 | Phase 1 | Advanced Lung Non-Small Cell Carcinoma | Oct 2027 |
| Clasp Therapeutics | CLSP-1025 HLA-A*02:01 specific T cell engager targeting p53 R175H mutation | TP53 | Phase 1 | Advanced Solid Tumor | Dec 2027 |
| Changchun GeneScience Pharmaceutical | GenSci128 TP53 Y220C mutant stabilizer | TP53 | Phase 1 | Solid Tumors Harboring a TP53 Y220C Mutation | Dec 2027 |
| Nutshell Therapeutics (Shanghai) | NTS071 TP53 Y220C mutant stabilizer | TP53 | Phase 1 | Advanced Solid Tumors | Dec 2028 |
Acute Myeloid Leukemia (4) Advanced Solid Tumor (2) Locally Advanced Nasopharyngeal Carcinoma (2) Nasopharyngeal Carcinoma (2) Malignant Solid Tumor (1) Advanced Soft-tissue Sarcoma (1) Sarcoma (1) Advanced Soft Tissue Sarcoma (1) Multiple Myeloma (1) Metastatic Pancreatic Cancer (1) TP53 Y220C Mutation (1) Myelodysplastic Syndrome (1)
small molecule (12), mixed (6), other (1)
First Affiliated Hospital, Sun Yat-Sen University (2) City of Hope Medical Center (2) Centre Leon Berard (1) Sarcoma Oncology Research Center, LLC (1) Institute of Hematology & Blood Diseases Hospital, China (1) SynerGene Therapeutics (1) PMV Pharmaceuticals (1) Kartos Therapeutics (1) Precigen (1) OSE Immunotherapeutics (1) Medical University of Vienna (1) Sun Yat-sen University (1) Fondazione Ricerca Traslazionale (1) Shanghai Jiao Tong University School of Medicine (1) AeRang Kim (1) Changchun GeneScience Pharmaceutical (1) Nutshell Therapeutics (Shanghai) (1) Chinese PLA General Hospital (1) Jacobio Pharmaceuticals (1) Clasp Therapeutics (1)
MDM2 (3) Tubulin (2) ERBB2 (2) CEA (2) PSMD1 (1) MYC (1) TYMS (1) RRM1 (1) MAGEA2 (1) MAGEA3 (1) MAGE2 (1) MAGE3 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.